Keyword
in
Collection
Date
to
Houston Voice, No. 920, June 12, 1998
File 009
Citation
MLA
APA
Chicago/Turabian
Houston Voice, No. 920, June 12, 1998 - File 009. 1998-06-12. University of Houston Libraries. University of Houston Digital Library. Web. July 3, 2020. https://digital.lib.uh.edu/collection/montrose/item/3055/show/3014.

Disclaimer: This is a general citation for reference purposes. Please consult the most recent edition of your style manual for the proper formatting of the type of source you are citing. If the date given in the citation does not match the date on the digital item, use the more accurate date below the digital item.

(1998-06-12). Houston Voice, No. 920, June 12, 1998 - File 009. Montrose Voice. University of Houston Libraries. Retrieved from https://digital.lib.uh.edu/collection/montrose/item/3055/show/3014

Disclaimer: This is a general citation for reference purposes. Please consult the most recent edition of your style manual for the proper formatting of the type of source you are citing. If the date given in the citation does not match the date on the digital item, use the more accurate date below the digital item.

Houston Voice, No. 920, June 12, 1998 - File 009, 1998-06-12, Montrose Voice, University of Houston Libraries, accessed July 3, 2020, https://digital.lib.uh.edu/collection/montrose/item/3055/show/3014.

Disclaimer: This is a general citation for reference purposes. Please consult the most recent edition of your style manual for the proper formatting of the type of source you are citing. If the date given in the citation does not match the date on the digital item, use the more accurate date below the digital item.

URL
Embed Image
Compound Item Description
Title Houston Voice, No. 920, June 12, 1998
Contributor
  • Hennie, Matthew A.
Publisher Window Media
Date June 12, 1998
Language English
Subject
  • LGBTQ community
  • LGBTQ people
  • Gay liberation movement
Place
  • Houston, Texas
Genre
  • newspapers
Type
  • Text
Identifier OCLC: 31485329
Collection
  • University of Houston Libraries Special Collections
  • LGBT Research Collection
  • Montrose Voice
Rights In Copyright
Note This item was digitized from materials loaned by the Gulf Coast Archive and Museum (GCAM).
Item Description
Title File 009
Transcript BTG PHARMACEUTICALS OXANDRIN* -O oxandrolone tablets ^-^ Revised. May 1996 Cholestatic hepatitis and <a una ice may oc alkylated androgens at a relatively low dose It lis wilh jaundice appears or il liver lunclion tests become abnormal, oxandrolone should be discontinued and the etiology should be determined Drug-induced jaundice is reversible when ive ingredienls include cornstarch, lactose, magnesium e. and hydroxypropyl methytoelhilose CLINICAL PHARMACOLOGY Certain clinical effects and adverse reac androgenic properties of this class ol drugs Complete dissociation of anabolic and androgenic eltects has not been achieved. The actons ol anabobc steroids are thetelore similar lo those ol of growth and sexual 0* itopment il given to young n. Anabolic sleroids suppress lhe gonadotropic functions ol the prlutary and may exert a direct etfed upon the testes. During exogenous admintslrahon ol anabolic androgens, endogenous testosterone release is inhibited Ihrough inhibition ol pituitary kileintfing hormone (LH). At large doses, spermatogenesis may be suppressed Ihrough feedback inhibition ol pituitary follicle-slimulaling hormone (FSM). Anabokc steroids have been reported lo increase low-density tipopiotems and decrease high-density lipoproteins. These levels revert lo normal on disconiinoalion ol treatment. INDICATIONS AND USAGE Oxandrin is indicated as adjunctive therapy lo promote weight gain alter weight loss bHowing extensive surgery, chronic infections, or severe Irauma. and in some palients who without definite pathophysiologic reasons laii lo longed admmrslralion of corticosteroids, and lor the relief ol Ih bone pain frequently accompanying osteoporosis (Se DOSAGE AND ADMINISTRATION) DRUG ABUSE ANO Di Oxandrolone is classified a* Anabolic Steroids Control Act ot 1990 and hs to Schedule III (non-narcolic) CONTRAtNDtCATKWS .. Pregnancy, because of possible mascutmizatlon of Ihe fetus. Oxandnn has been shown to cause embryotoxicity. [ototoxicity infertility, and masculinization ol female animal ollspring when given in doses 9 times Ihe human E HypncatoenM WARNINGS PELIOSIS HEPATIS. A CONDITION IN WHICH LIVER AND SOMETIMES SPLENIC TISSUE IS REPLACED WITH BLOOD-FILLED CYSTS. HAS BEEN REPORTED IN PATIENTS RECEIVING ANDROGENIC ANABOLIC STEROID THERAPY THESE CYSTS ARE SOMETIMES PRESENT WITH MINIMAL HEPATIC UfSFUNCTION. BUT AT OTHER TIMES THEY HAVE BEEN ASSOCIATED WITH LIVER-FAILURE THEY ARE OFTEN NOT RECOGNIZED UNTIL LIFE THREATENING LIVER FAILURE OR INTRA-ABDOMINAL HEMORRHAGE DEVELOPS. WITHDRAWAL OF DRUG USUALLY RESULTS IN COMPLETE DISAPPEARANCE OF LESIONS LIVER CELL TUMORS ARE ALSO REPORTED MOST OFTEN THESE TUMORS ARE BENIGN AND ANDROGEN DEPENDENT BUT FATAL MALIGNANT TUMORS HAVE BEEN REPORTED WITHDRAWAL OF DRUG OFTEN RESULTS IN REGRESSION OR CESSATION OF PROGRESSION OF THE TUMOR HOWEVER. HEPATIC TUMORS ASSOCIATED WITH ANDROGENS OR ANABOLIC STEROIDS ARE MUCH MORE VASCULAR THAN OTHER HEPATIC TUMORS AND MAY BE SILENT UNTIL LIFE-THREATENING INTRAABDOMINAL HEMORRHAGE DEVELOPS BLOOD LIPID CHANGES THAT ARE KNOWN TO BE ASSOCIATED WITH INCREASED RISK OF ATHEROSCLEROSIS ARE SEEN IN PATIENTS TREATED WITH AN0ROGENS OR ANABOLIC STEROIDS THESE CHANGES INCLUDE DECREASED HIGHDENSITY LIPOPROTEINS AND SOMETIMES INCREASED LOW-DENSITY LIPOPROTEINS THE CHANGES MAY BE VERY MARKED AND COULD HAVE A SERIOUS IMPACT ON THE RISK OF ATHEROSCLEROSIS AND CORONARY ARTERY DISEASE In patients with breast cancer, anabolic steroid therapy may cause hypercalcemia by stimulating osteolysis Oxandrolone therapy should be discontinued if hypercalcemia occurs. ous complication in patients with preexisting cardiac, renal, or hepatic disease Concomitant administration of adrenal cortical steroid or ACTH may increase Ihe edema. In children, androgen therapy may accelerate Oone maturation without producing compensatory gam in linear growth This adverse effect results in compromised adult heighl The younger Ihe child. Ihe greater the risk ol compromising final mature heighl The effect on bone maturation should be monitored by assessing bone age of the fell wrist and hand every 6 months iSee PRECAUTIONS: Laboratory tests; Geriatric palienls trealed with androgenic anabolic sleroids may be at an increased risk lor the development ol prostatic hypertrophy and proslalic carcinoma. ANABOLIC STEROIDS HAVE NOT BEEN SHOWN TO ENHANCE ATHLETIC ABILITY PRECAUTIONS Women should be observed lor signs ol virilization (deepening of the voce, hirsutism, acne, clitoromegaly) Discontinuation of drug therapy at the lime of evidence ol mild virilism is necessary ration. Some virilizing changes women are irreversible even alter prompt discontinuance ol Iherapy and are nol prevented by conconWanl use 01 estrogens. Menstrual irregularities may also occur Anabolic steroids may cause suppression of clotting (actors II. V VII. a The physician should mstrucl patients ti lowing side effects ot androgens: Males Too Irequenl or persistent ei r aggravation ol acne report any ol fhe lo All pahents. Nausea, vomiting, changes in skin color, or ankle swelling Laboratory tests: Women wilh disseminated breasl carcinoma should have he quent determination of urine and serum calcium levels during the course of therapy (See WARNINGS) Because of Ihe hepatotoxicity associated wilh the use ol 17- alph a-alkylated androgens, liver lunction tesls should be obtained periodically. Periodic (every 6 monlhs) should be made during treatr rate ot bone maturation and the effects of androgen Iherapy the epiphyseal centers Serum lipids and high-density lipoprotein cholesterol determinations should be done periodically as androgenic anabolic steroids have been reported lo increase low-density lipoproteins. Serum cholesterol levels may increase dunng therapy Therefore, caution is required when admmistenng Ihese agents to palients with a history ol myocardial infarction or coronary artery disease Serial determinations ol serum cholesterol should be made and therapy adjusted accordingly Hemoglobin and hemalocrrl should be checked periodealy lor polycythemia in palienls who are receiving high doses ol anabolic steroids. Drug interac lions Anticoagulants: Anabolic steroids may increase sensitivity lo oral anticoagulants Dosage ot the anticoagulant may have lo be decreased in order lo maintain desired prothrombin time Patents receiving oral anticoagulant therapy require close monilonng. especially when anabolic sleroids are started or slopped. Oral hypoglycemic agents: Pregnancy: Teratogenic eHecIs — Pregnancy Category X (See CONTRAINDICATIONS) It is not known whether anabolic steroids are excreted in human milk. Because of the potential ol serious adverse reactions in nursing mlanis Irom oxandrolone, a decision should be made whether lo discontinue nursing oi lo discontinue the drug, taking into account the importance of the drug lo Ihe mother Pediatric use: Anabolic agents may accelerate epiphyseal maturation more rapidly lhan linear growth in children and Ihe effect may continue br 6 monlhs after the drug has been slopped. Therefore. Iherapy should be monitored by x-ray sludies at 6-monlh intervals in order lo avoid trie risk ol compromising adult heighl. Androgenic anabolic steroid Iherapy should be used very cautiously in children and only by specialists who are aware ol Ihe effects on bone maturation (See WARNINGS] ADVERSE REACTIONS The following adverse reactions have been associated wilh use of anabolic steroids: Hepatic Cholestatic jaundice with, rarely, hepatic necrosis and death. Hepatocellular neoplasms and poliosis hepalis with long- term Iherapy (Sea WARNINGS) Reversible changes in liver lunction tesls also occur including increased bromsulbphlhalein (BSP) retention, and increases in serum bilirubin, aspartate aminotransferase (AST. SGOT) and alkaline phosphatase. Prepubertal: Phallic enlargement and increased frequency or persistence ol erections. Poslputtertal Inhibition of testicular lunclion, testicular atrophy and oligospermia, impotence, chronic priapism, epididymis. CHtoral enlargement, rr CNS Habituation, excilation. insomnia, depression, and changes in libido Hematologic Bleeding in pabents on concomitant anticoagulant Iherapy Breast Gynecomastia. Larynx: Deepening ol Ihe voice in females. Haif Hirsutism and male pattern baldness in females Skin: Acne (especially in lemales and prepubertal males) Skeletal: Premature closure ol epiphyses in children (See PRECAUTIONS: Pediatric uw) Fluid and electrolytes: Edema, retention ol serum electrolytes (sodium chloride, potassium, phosphate, calcium) MelJbolic. Endocrine Decreased glucose tolerance (See PRECAUTIONS: Laboratory tests) increased creatinine excretion, increased serum levels ol creatinine phosphokinase (CPK). Mascultm/ation of Ihe lelus. Inhibition of gonadolropin secretion. age OVERDOSAGE the No symptoms or signs associated with ot metabolism ot oral liypoglycerm Adrenal sleroids or ACTH: conical steroids or ACTH may increase the edema Drug/Laboratory test Interactions: Anabolic sleroids may decrease levels of thyroxine binding globulin, resulting in decreased lotai T, serum levels and increased resin uptake ol T, and T,. Free thyroid hormone levels remain unchanged In addition, a decrease m PBI and radioactive iodine uptake may occur. Carcinogenesis, mutagenesis, impairment ot fertility Animal data: Oxandrolone has nol been tested in laboratory animals tor carcinogenic or mutagenic effects In 2-year chronic oral rat studies, a dose related reduction of spermatogenesis and decreased organ weights (testes, prosfale. seminal vesicle uterus adrenals and pituitary) were shown mora have been reported m patienis receiving long- term Iherapy wilh androgenic anabolic steroids in high doses (See WARNINGS) Withdrawal ol Ihe drugs did not lead lo regression ot the tumors m all cases Geriatric patients treated hypertrophy and prostatic 5.000 mg/kg No specific antidote is known, but gastric lavage may boused DOSAGE ANO ADMINISTRATION Therapy with anabolic steroids is adjunctive to and not a replacement for conventional Iherapy The duration of Iherapy wilh Oxandrin (oxandrolone) will depend on the response ol the patienl and the possible appearance of adverse read Ions Therapy should be intermittent Adults.The usual adull dosage of Oxandrin is one 2.5-mg tablet 2 lo 4 limes daily However, Ihe response of individuals lo anabolic steroids varies, and a dally dosage of as little as 2.5 mg or response A course ol iherapy ol 2 to 4 weeks is usually adequate This may be repeated intermittently as indicated Children: For children fhe total daily dosage ol Oxandrin is <0.1 mg per kilogram body weighl or <0.045 mg per pound of body weigh) This may be repeated intermittently as Indicated HOW SUPPLIED Oxandrin 2 5-mg laWels are oval, white, and scored with BTG on one side and "11" on each side of the scoreline on the other side, bottles ol 100 (NDC 54396* 111*11) Caution: Federal law prohibits dispensing wilhoul prescription Chicago. IL 60680 Address medical inquiries to Medical Affairs 70 Wood Avenue South Iselm. NJ 08830 ie development ol proslalic BTG PHARMACEUTICALS BTG PHARMACEUTICALS OXANDRIN oxandrolone tablets ©
File Name uhlib_31485329_n920_008.jpg